There is still plenty of reason to worry about unproven stem cells being marketed in the U.S. and elsewhere around the world. I’ll start with a new item here in the U.S. on a firm called MD Stem Cells and end with a newly published paper about how things are going in Poland on this […]
Weekly reads: MD Stem Cells, embryo models & headaches, cell therapy trial updates Read More »
Researchers have been making stem cell-based embryo models for years now and a few folks have taken to calling these “stembryos.” Other names like gastruloids and blastoids are sometimes used too. “Embryo models” might be the simplest and best name. The embryo model research has advanced relatively quickly from very basic, not very organized structures
Weekly reads: stembryos or human embryo models, new Macchiarini sentence Read More »
There seems to be a never-ending supply of stem cell for hair loss research but a new article invokes a novel mechanism. Stem cell for hair loss research and cell mechanics Here’s a recent news item about a PNAS paper: Coaxing hair growth in aging hair follicle stem cells, NW Now. A common theme is things
Weekly reads: stem cell for hair loss, clinic lawsuit update, 2 big retractions Read More »
I’m kind of in grant writing hell at the moment, as many of you may have been at various times, but I’m still finding time to read a little on cell therapy and stem cell research. Here are some things that caught my eye as I work on multiple grants with impending deadlines. Clinical trials
Weekly reads: cell therapy trials, melanoma, β-thalassemia Read More »
So many things have gotten very expensive these days that it got me thinking this past week again about stem cell cost. For this reason, I’ve been running polls asking people what they’ve paid for stem cells and how many therapies they’ve gotten. Before jumping into our weekly reads, check out our informational post on
Weekly reads: stem cell cost, trial death, HSCT for MS, Neuralink Read More »
Totipotency literally means all powerful, but it refers in biology to specific cells. These cells can make every type of cell in the body of an organism plus the extraembryonic tissues needed for development. This includes humans. So if you could reprogram human cells like blood or skin cells into totipotent stem cells, you might
Weekly reads: gene therapy nod, Nature pub ethics, CRISPR LDL Read More »
I’ve written before about Liz Parrish and her life-extension firm BioViva. Now they appear to have connections with another entity called Integrated Health Systems or IHS, according to a new Wired article. Some of what is going on with IHS and maybe BioViva in Mexico seems extremely risky to me. BioViva, Parrish, and Integrated Health Systems The
Weekly reads: BioViva & life-extension clinic, RMATs, universal cells Read More »
I’ve been writing The Niche now for more than 13 years and the idea of stem cells for ALS has been around that whole time. Unfortunately, it has been slow going on this front, but there are still reasons for hope. Probably now much more than ever before. I’ll start with news on one path
Weekly reads: stem cells for ALS, cell wrinkles, editors quit Read More »
It’s mostly been a week of good and encouraging news in the regenerative medicine space including with gene therapies maybe with the exception of some eye drops warnings (more below). There’s realistic hope for an approved sickle cell disease soon. I also see some long-term positive news on hearing loss research. Hematopoietic stem cell transplant
Weekly reads: reprogramming hearing loss, heart disease, eye drops, sickle cell Read More »
It’s a big challenge to get a cell therapy approved by the FDA and if you look at my list of FDA-approved stem cell therapies, it’s not as long as we might hope. FDA OK on cell therapy from Gamida Cell For this reason, it was excellent news to see that the FDA approved a
Weekly reads: FDA nod on new cell therapy, gray hair, pong-playing cells Read More »